“Molecular Integrative Oncology In Addition to – Not instead of – Conventional Oncology Treatment”

“Molecular Integrative Oncology: In Addition to – Not instead of – Conventional Oncology treatment” (William LaValley, MD) [#134] Brad Power March 12, 2025 “Seeing all the components in the tumor microenvironment through that lens of pro-cancer, anti- cancer directionality places a perspective for searching as well as understanding the information that's in the literature and that provides a structural framework for making choices and decisions about therapeutic agents.

” – William LaValley, MD “Because the cancer cells are producing molecules that induce or recruit, or could even be thought of as coerce and kidnap other cells that are good, desirable, necessary, normal, healthy cells in other circumstances and in other locations, now are forced into the service of supporting and maintaining and camouflaging the cancer cells.

That means that we have to consider all of these cells concurrently and take an integrative, networked perspective of how to manage these multiple cell types concurrently to control the progression of the cancer, in addition to whatever is the conventional treatment, targeted treatment, immune-targeted treatment, conventional cytotoxic therapy, radiotherapy or other ablation therapies, all of those, in addition to this pre- clinical trial data access to make therapeutic choices about products that are already available, natural products and repurposed pharmaceuticals.

” – William LaValley, MD Meeting Summary A cancer diagnosis can feel scary and overwhelming. Your doctor will typically focus on standard care—surgery, chemotherapy, radiation, immunotherapy—but may not know much about complementary treatments that can increase the effectiveness of standard care. Many cancer patients search for ways to boost their health and immune system.

Reliable information is hard to find and even harder to turn into a safe plan. Working with a doctor or nurse trained in complementary treatments can help you make healthy choices like eating well, lowering stress, sleeping enough, and exercising. Most patients considering natural supplements or repurposed drugs want scientific evidence and medical guidance. Dr.

William LaValley is uniquely qualified to talk about a scientific approach to complementary cancer therapies. He has spent 36 years treating patients, and 25 years studying cancer biology. His “Molecular Integrative Oncology” protocols use research to create safe, targeted treatment plans that add to—not replace—standard care.

These plans use natural compounds and repurposed medications backed by studies, designed to slow cancer growth and improve life quality. Patients or doctors contact Dr. LaValley to create personalized, evidence-based plans for local doctors to deliver. Why do you need to understand the scientific approach to complementary molecular integrative oncology?

●Targets many parts of the tumor environment for stronger results.

sonalized, evidence-based plans for local doctors to deliver. Why do you need to understand the scientific approach to complementary molecular integrative oncology? ●Targets many parts of the tumor environment for stronger results. ●Uses data on molecular pathways to understand cancer’s complexity. ●Chooses natural products and repurposed drugs based on research, not guesswork. What are the key elements of the molecular integrative oncology model?

“Molecular Integrative Oncology: In Addition to – Not instead of – Conventional Oncology treatment” (William LaValley, MD) [#134] ●Focuses on cancer as a network of pathways, not just single cells. ●Uses drugs already proven safe in other treatments for cancer effects. ●Identifies “pro-cancer” and “anti-cancer” processes to guide therapy.

●Builds on scientific evidence while adding to standard treatments. What do you need to do to access this molecular integrative oncology approach (outside of standard care)? ●Work with an integrative doctor trained in natural and repurposed therapies. ●Get a personalized plan, reviewed and approved by your doctor. ●Start with low doses, increase slowly, and track results closely.

●Understand that risks exist due to limited clinical trials. What are examples of treatment plans of evidence-supported and evidence-based recommendations using molecularly-targeted natural product supplements and re- purposed off-label drug protocols? ●Natural compounds like curcumin, green tea extract, or resveratrol with low-dose drugs like metformin.

●Anti-angiogenic supplements to block tumor blood supply. ●Immunity-boosting natural products plus repurposed immunotherapies. ●Agents that target cancer stem cells and key growth pathways. How should you administer these natural and off-label products?

●Start with very low dosages ●Gradually escalate ●Closely track cause and effect ●Ensure treatment remains well-tolerated ●Reassess every three months What are the potential risks of pursuing therapeutic interventions without comprehensive molecular insights into the tumor microenvironment? ●Unknown side effects or serious reactions.

●Reduced effectiveness if treatments aren’t well-matched to cancer biology. ●Resistance or poor tolerance if dosing isn’t carefully managed. How can you learn more? ●Reach out to Dr. LaValley through his website at https://lavalleymdprotocols.com/ ●Explore the use of liquid biopsies and cell-free DNA analysis to monitor the effectiveness of therapeutic interventions.

“Molecular Integrative Oncology: In Addition to – Not instead of – Conventional Oncology treatment” (William LaValley, MD) [#134] ○“Evaluating Complementary Therapies in Cancer Care” (Martin Lužbeták, MD, MS) [#108] ○"A Patient’s View on Nutrition, Supplements, Integrative Oncology, and Complementary Therapies" (Robert Ellis and Glenn Sabin) [#33] ○"Terrain and the Whole Person in Cancer Care” (Nasha W

Valley, MD) [#134] ○“Evaluating Complementary Therapies in Cancer Care” (Martin Lužbeták, MD, MS) [#108] ○"A Patient’s View on Nutrition, Supplements, Integrative Oncology, and Complementary Therapies" (Robert Ellis and Glenn Sabin) [#33] ○"Terrain and the Whole Person in Cancer Care” (Nasha Winters, ND, FABNO) [#95] ○“Integrative Cancer Care” (Donald Abrams, MD) [#102] ○“Cancer Scams: Don’t Get Taken” (Bapcha Murty) [#94] The information and opinions expressed on this website or platform, or during discussions and presentations (both verbal and written) are not intended as health care recommendations or medical advice by Cancer Patient Lab, its principals, presenters, participants, or representatives for any medical treatment, product, or course of action.

You should always consult a doctor about your specific situation before pursuing any health care program, treatment, product or other course of action that might affect your health.

“Molecular Integrative Oncology: In Addition to – Not instead of – Conventional Oncology treatment” (William LaValley, MD) [#134] Meeting Notes KEYWORDS Molecular integrative oncology, tumor microenvironment, pro-cancer, anti-cancer directionality, natural products, repurposed pharmaceuticals, pre-clinical trial data, cancer stem cells, vascular cells, immune cells, stromal cells, network pharmacology, personalized treatment plans, therapeutic interventions, molecular pathways.

SPEAKERS Will LaValley (88%), Roger Royse (4%), Cindy Ness (4%), John P (4%), David Plunkett (1%) CHAT CONTRIBUTORS Roger Royse, Helen, Saed Sayad, Koryn DelPrince, Michael - Denver SUMMARY Will LaValley discussed the emerging field of molecular integrative oncology, emphasizing the use of a broad spectrum of therapeutic agents, including natural health products and repurposed pharmaceuticals.

He highlighted the importance of understanding the tumor microenvironment, focusing on cancer cells, cancer stem cells, vascular cells, immune cells, and stromal cells. LaValley explained the concept of pro-cancer and anti-cancer directionality, guiding therapeutic interventions.

He noted the lack of clinical trial data but stressed the potential of pre-clinical trial data to inform treatment plans. LaValley also addressed the challenges of managing treatment tolerance and the potential for resistance, advocating for a personalized, integrative approach.

OUTLINE Molecular Integrative Oncology Overview ●Will LaValley introduced the concept of molecular integrative oncology, emphasizing its role in managing cancer. ●He referenced a landmark journal issue in Seminars in Cancer Biology, highlighting the use of a broad spectrum of therapeutic agents.

●The project involved 300 cancer researchers and oncology doctors, focusing on controlling cancer progression by intervening at each hallmark. ●He stressed the importance of pre-clinical trial data in guiding molecular integrative oncology.

f therapeutic agents. ●The project involved 300 cancer researchers and oncology doctors, focusing on controlling cancer progression by intervening at each hallmark. ●He stressed the importance of pre-clinical trial data in guiding molecular integrative oncology. Understanding the Tumor Microenvironment ●The tumor microenvironment, including cells and molecules within it, is important.

“Molecular Integrative Oncology: In Addition to – Not instead of – Conventional Oncology treatment” (William LaValley, MD) [#134] ●The concept of pro-cancer and anti-cancer directionality helps explain molecular pathways, how cells and molecules interact. ●The tumor microenvironment is divided into four main categories: cancer cells, cancer stem cells, vascular cells, and stromal cells.

●The role of vascular cells is supplying oxygen to cancer cells and there are interactions between cancer cells and immune cells. ●It is important to target pro-cancer molecular pathways with anti-cancer interventions. ●The imagery of cellular and molecular meetups describes how cells communicate and affect each other. ●Pre-clinical trial data can be used to make informed therapeutic decisions.

Challenges and Opportunities in Therapeutic Interventions ●Managing the tumor microenvironment is complicated. ●An integrative, networked perspective is needed to manage multiple cell types. ●Natural products and repurposed pharmaceuticals can be used for therapeutic interventions. ●It’s important to start with low doses and gradually increase to ensure comfort and tolerance.

Personalized treatment Plans ●John asked about the inputs used to identify cells in the tumor microenvironment and shared his experience with next-generation sequencing. ●Dr. LaValley explained the framework for pursuing information about cell types and molecular interactions and the limitations of current protocols and the potential for future advancements in understanding.

●John inquired about the use of liquid biopsies for monitoring treatment effectiveness. ●Dr. LaValley acknowledged the value of liquid biopsies and their potential for providing real-time information. ●Cindy Ness asked about the application of tumor microenvironment emphasis in standard of care institutions. ●Dr.

LaValley described the collaborative process with local integrative medicine physicians to implement treatment plans. ●treatment plans need to fit the workflow of local physicians. ●Roger Royse asked about preventing resistance to therapeutic interventions, especially micro-dosing. ●Dr.

LaValley explained the importance of targeting multiple molecular sites simultaneously to decrease compensatory signaling. ●Natural products and repurposed pharmaceuticals can enhance chemo sensitivity and decrease chemo resistance. ●Cindy Ness inquired about the influence of epigenetics and ethnicity on the tumor microenvironment. ●Dr.

LaValley acknowledged the impact of epigenetics but noted the lack of specific information on ethnicity.